Kareus begins Phase I testing of first-in-class Alzheimer's drug
This article was originally published in Scrip
Executive Summary
Private biotechnology company, Kareus Therapeutics, has begun a Phase I trial of KU-046 – the first in a new class of drugs for Alzheimer's disease, discovered using the firm's proprietary bioenergetics and KARLECT platforms, it says.